RT Journal Article
SR Electronic
A1 Nierengarten, Mary Beth
T1 Efficacy of Secukinumab Sustained over Time for Treatment of Active PsA
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 51
SP 14
OP 15
DO 10.1177/155989771451011
UL http://mdc.sagepub.com/content/14/51/14.abstract
AB This article presents the results of the Efficacy at 24 Weeks and Long-Term Safety, Tolerability, and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) study [FUTURE 1; NCT01392326]. FUTURE 1 is a multicenter, placebo-controlled phase 3 study in which 606 patients with PsA received an intravenous loading dose of secukinumab at 10 mg/kg every 2 weeks for the first 4 weeks, followed by subcutaneous doses of 75 mg (n=202) or 150 mg (n=202) monthly, compared with placebo (n=202).